NO20016088L - Nervebeskyttende og retinobeskyttende oftalmologiske medisiner - Google Patents

Nervebeskyttende og retinobeskyttende oftalmologiske medisiner

Info

Publication number
NO20016088L
NO20016088L NO20016088A NO20016088A NO20016088L NO 20016088 L NO20016088 L NO 20016088L NO 20016088 A NO20016088 A NO 20016088A NO 20016088 A NO20016088 A NO 20016088A NO 20016088 L NO20016088 L NO 20016088L
Authority
NO
Norway
Prior art keywords
protective
ramiprilat
medicine
visual
acuity
Prior art date
Application number
NO20016088A
Other languages
English (en)
Norwegian (no)
Other versions
NO20016088D0 (no
Inventor
Raouf Rekik
Original Assignee
Raouf Rekik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9915359A external-priority patent/FR2794975A1/fr
Application filed by Raouf Rekik filed Critical Raouf Rekik
Publication of NO20016088D0 publication Critical patent/NO20016088D0/no
Publication of NO20016088L publication Critical patent/NO20016088L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20016088A 1999-06-16 2001-12-13 Nervebeskyttende og retinobeskyttende oftalmologiske medisiner NO20016088L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TN99122 1999-06-16
FR9915359A FR2794975A1 (fr) 1999-06-16 1999-12-06 Medicaments opthalmologiques neuro et retino-protecteurs
PCT/FR2000/001679 WO2000076499A2 (fr) 1999-06-16 2000-06-16 Medicaments ophtalmologiques neuro-et retino-protecteurs

Publications (2)

Publication Number Publication Date
NO20016088D0 NO20016088D0 (no) 2001-12-13
NO20016088L true NO20016088L (no) 2002-02-12

Family

ID=26235177

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20016088A NO20016088L (no) 1999-06-16 2001-12-13 Nervebeskyttende og retinobeskyttende oftalmologiske medisiner

Country Status (20)

Country Link
US (1) US7049340B1 (sl)
EP (1) EP1185255B1 (sl)
JP (1) JP2003501461A (sl)
AT (1) ATE424819T1 (sl)
AU (1) AU6449000A (sl)
BR (1) BR0011714A (sl)
CA (1) CA2376909A1 (sl)
CZ (1) CZ20014516A3 (sl)
DE (1) DE60041765D1 (sl)
DK (1) DK1185255T3 (sl)
ES (1) ES2324200T3 (sl)
HU (1) HUP0201478A3 (sl)
MA (1) MA26798A1 (sl)
MX (1) MXPA01012907A (sl)
NO (1) NO20016088L (sl)
PL (1) PL352365A1 (sl)
SI (1) SI1185255T1 (sl)
SK (1) SK18772001A3 (sl)
TR (1) TR200103665T2 (sl)
WO (1) WO2000076499A2 (sl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2826276A1 (fr) * 2001-06-20 2002-12-27 Raouf Rekik Administration des inhibiteurs de l'enzyme de conversion de l'angiotensine dans les degradations visuelles des sujets ages dues a la presbytie
AU2007249399A1 (en) * 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
TNSN08110A1 (en) * 2008-03-11 2009-07-14 Rekik Raouf Dr Drug delivery to the anterior and posterior segment of the eye from drops
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
RU2471454C2 (ru) * 2010-12-14 2013-01-10 Валерий Викторович Педдер Способ лечения дистрофических заболеваний сетчатки глаза
JP6238977B2 (ja) * 2012-06-29 2017-11-29 ラオフ・レキク 視神経症または先天性視神経萎縮を治療するためのアンギオテンシン変換酵素阻害薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0114333B1 (en) * 1982-12-27 1990-08-29 Schering Corporation Pharmaceutical composition
DE3410732A1 (de) * 1984-03-23 1985-09-26 Hoechst Ag, 6230 Frankfurt Methode zur behandlung des glaukoms
US4656188A (en) * 1985-10-09 1987-04-07 Merck & Co., Inc. Ace inhibitors in macular degeneration
JPH05306296A (ja) * 1992-04-24 1993-11-19 Marino Forum 21 魚類由来ペプチドとその製法
AU2089099A (en) * 1998-01-16 1999-08-02 Alcon Laboratories, Inc. Topical administration of angiotensin-converting enzyme inhibitors

Also Published As

Publication number Publication date
ES2324200T3 (es) 2009-08-03
JP2003501461A (ja) 2003-01-14
AU6449000A (en) 2001-01-02
MA26798A1 (fr) 2004-12-20
HUP0201478A2 (hu) 2002-11-28
NO20016088D0 (no) 2001-12-13
US7049340B1 (en) 2006-05-23
PL352365A1 (en) 2003-08-25
BR0011714A (pt) 2002-03-05
ATE424819T1 (de) 2009-03-15
HUP0201478A3 (en) 2004-05-28
SK18772001A3 (sk) 2002-04-04
CZ20014516A3 (cs) 2002-05-15
SI1185255T1 (sl) 2009-08-31
EP1185255A2 (fr) 2002-03-13
WO2000076499A2 (fr) 2000-12-21
WO2000076499A3 (fr) 2001-05-17
MXPA01012907A (es) 2003-06-24
TR200103665T2 (tr) 2002-10-21
DE60041765D1 (de) 2009-04-23
DK1185255T3 (da) 2009-07-06
EP1185255B1 (fr) 2009-03-11
CA2376909A1 (fr) 2000-12-21

Similar Documents

Publication Publication Date Title
HK1015691A1 (en) Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia.
WO2004028570A3 (en) A method for treating severe tinnitus
WO2001036510A3 (en) Use of poly(diallylamine) polymers
US10188676B2 (en) Anti-inflammatory solution
EP1074258A3 (en) Methods and compositions for treating diseases and conditions of the eye
NO20016088L (no) Nervebeskyttende og retinobeskyttende oftalmologiske medisiner
RU2001118854A (ru) Оптически активное производное пиридил-4н-1,2,4-оксадиазина и его применение при лечении сосудистых заболеваний
Egorov et al. Histochrome, a new antioxidant, in the treatment of ocular diseases
Boda et al. Low molecular weight heparin as thromboprophylaxis in familial thrombophilia during the whole period of pregnancy
HK124595A (en) Anthocyanidins for the treatment of ophthalmic diseases
WO1995016435A3 (en) Improved intraocular irrigating solution containing non-steroidal antiinflammatory agent
Akkan et al. Penetration of topically applied ciprofloxacin, norfloxacin and ofloxacin into the aqueous humor of the uninflamed human eye
WO1998024898A3 (en) Therapeutic composition comprising the kal protein and use of the kal protein
AU2001223953A1 (en) Use of l-carnitine as stabilizing agent of proteins
RU2290191C2 (ru) Способ лечения туберкулезных увеитов
CY1110476T1 (el) Οφθαλμολογικα φαρμακα προστατευτικα του αμφιβληστροειδους τα οποια περιεχουν ραμιπριλη ή ραμιπριλατη
Khare Pyrrolidinomethyltetracycline in cavernous sinus thrombosis.
WO2007036920A3 (en) Therapeutic use of polyanhydroglucronic acid
RU2148972C1 (ru) Способ лечения гемофтальма
RU2077877C1 (ru) Способ лечения сосудистой патологии глаз
Barsky Central retinal vein occlusion treated with anticoagulant and steroid therapy: case report and discussion
RU93021719A (ru) Способ лечения отслойки сетчатки
Goldberg Comparison of tropical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J. Glaucoma 2001; 10: 414-22
RU94024966A (ru) Средство для улучшения процессов микроциркуляции и коррекции иммуногемостатических нарушений при лечении глазных заболеваний
RU96111078A (ru) Способ выбора медикаментозного лечения тромбозов ретинальных вен

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application